| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/03/2003 | US20030124196 Pulsatile release compositions and methods for enhanced intestinal drug absorption |
| 07/03/2003 | US20030124176 Use of a base in order to increase the flux of the active agent through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. |
| 07/03/2003 | US20030124173 Manufacturing therapeutic enclosures |
| 07/03/2003 | US20030124169 Biocompatible, biodegradable matrix and a protein, produced by expression of recombinant DNA capable of inducing endochondral bone formation in association with said matrix |
| 07/03/2003 | US20030124152 Treating and preventing intrinsic and extrinsic aging of the skin and methods for treatment and prevention of skin aging |
| 07/03/2003 | US20030124147 Fusion toxin comprising the toxin domain of diphtheria toxin and a urokinase-type plasminogen activator domain; killing tumor cells, especially glioblastoma cells |
| 07/03/2003 | US20030124144 Chimeric capsid proteins and uses thereof |
| 07/03/2003 | US20030124141 Helicobacter polypeptides and corresponding polynucleotide molecules |
| 07/03/2003 | US20030124140 Ovarian tumor polypeptides, polynucleotides that encode them, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells |
| 07/03/2003 | US20030124136 Immunotherapy for reversing immune suppression |
| 07/03/2003 | US20030124135 Recombinant intracellular pathogen vaccines and methods for use |
| 07/03/2003 | US20030124133 Polypeptide having a first domain with carbohydrate binding activity and a second domain with kinase activity; tumor immunotherapy |
| 07/03/2003 | US20030124132 Using targeted or non-targeted coagulants to cause tumor vasculature thrombosis. |
| 07/03/2003 | US20030124131 Immunoconjugates of toxins directed against malignant cells |
| 07/03/2003 | US20030124126 Nucleic acid compositions encoding mammalian DGAT2 alpha and MGAT1 polypeptide products; identifying acyltransferase inhibitors; producing triglycerides |
| 07/03/2003 | US20030124125 Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10 |
| 07/03/2003 | US20030124123 Also an IL-12 anti-idiotype antibody to the antibody |
| 07/03/2003 | US20030124121 Treating septic arthritis |
| 07/03/2003 | US20030124118 Pharmaceutical composition comprising factor VII polypeptides and protein S inhibitors |
| 07/03/2003 | US20030124116 Antibodies binding to polypeptides encoded by the genes |
| 07/03/2003 | US20030124115 A carboxy terminal peptide fragment of thrombopoietin is fused with the carboxy terminal of human erythropoietin; highly enhanced in vivo half-life due to increased carbohydrate content; no antigenicity |
| 07/03/2003 | US20030124113 Human apoptosis associated proteins |
| 07/03/2003 | US20030124111 Antimicrobial agent |
| 07/03/2003 | US20030124110 Use of modified lysozyme c to prepare medicinal compositions for the treatment of some serious diseases |
| 07/03/2003 | US20030124109 Prevention and treatment of mycoplasma-associated diseases |
| 07/03/2003 | US20030124108 Useful in wound healing, autoimmune disorders and inflammatory diseases |
| 07/03/2003 | US20030124107 PAK5-related compositions and methods |
| 07/03/2003 | US20030124106 Diagnosing, treating, or preventing disorders associated with expression of ORP. |
| 07/03/2003 | US20030124105 Programmed cell death genes and proteins |
| 07/03/2003 | US20030124097 Method to improve the safety of gene therapy |
| 07/03/2003 | US20030124095 Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex |
| 07/03/2003 | US20030124094 Increasing or maintaining the blood supply in the penis |
| 07/03/2003 | US20030124093 Method for treating kidney disorders |
| 07/03/2003 | US20030124092 IL-17 like molecules and uses thereoflike molecules and uses thereof |
| 07/03/2003 | US20030124091 Administration of the factor with a vaccine to enhance immune response |
| 07/03/2003 | US20030124087 Prevents an adhesion between tissues at an operated legion and have various shapes, comprising sodium carboxymethyl cellulose and gellan gum |
| 07/03/2003 | US20030124058 Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| 07/03/2003 | US20030124056 Carrier molecules |
| 07/03/2003 | CA2849201A1 Adipose-derived cell processing unit |
| 07/03/2003 | CA2476755A1 Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
| 07/03/2003 | CA2471417A1 Uses of an endothelial cell receptor |
| 07/03/2003 | CA2471373A1 Modified tridegins, their preparation and their use as transglutaminase inhibitors |
| 07/03/2003 | CA2471355A1 Substituted diketopiperazines as oxytocin antagonists |
| 07/03/2003 | CA2471241A1 Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant |
| 07/03/2003 | CA2471145A1 Dna encoding novel cyclic gmp dependent protein kinases from two protozoal sources for use as chemotherapeutic targets for antiprotozoal agents |
| 07/03/2003 | CA2471110A1 Peptides for treatment of the human papillomavirus(hpv)-associated cancer and other epithelial tumors |
| 07/03/2003 | CA2471096A1 Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
| 07/03/2003 | CA2470938A1 Treatment of ebv and khsv infection and associated abnormal cellular proliferation |
| 07/03/2003 | CA2470900A1 Compositions and methods for the diagnosis and treatment of tumor |
| 07/03/2003 | CA2470776A1 Malleable protein matrix and uses thereof |
| 07/03/2003 | CA2470603A1 Methods for the treatment of peripheral neural and vascular ailments |
| 07/03/2003 | CA2470594A1 Leptin proteins |
| 07/03/2003 | CA2470576A1 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 07/03/2003 | CA2470063A1 Parmaceutical agents and methods for tissue and vascular regeneration |
| 07/03/2003 | CA2470031A1 Systems and methods for treating patients with collagen-rich material extracted from adipose tissue |
| 07/03/2003 | CA2469972A1 Bone polypeptide-1 |
| 07/03/2003 | CA2469941A1 Novel nucleic acids and polypeptides |
| 07/03/2003 | CA2469918A1 Method for preparing echinocandin derivatives and their compositions |
| 07/03/2003 | CA2469370A1 Adipose-derived cell processing unit |
| 07/03/2003 | CA2469263A1 Raf/ras binding compounds |
| 07/03/2003 | CA2468882A1 A library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism |
| 07/03/2003 | CA2468100A1 Insulin molecule having protracted time action |
| 07/03/2003 | CA2468083A1 Use of heterocyclic carboxamides to treat anemia |
| 07/03/2003 | CA2466633A1 Sustained-release compositions |
| 07/03/2003 | CA2465890A1 Aqueous sustained-release formulations of proteins |
| 07/03/2003 | CA2462670A1 Sperm-specific cation channel, catsper2, and uses therefor |
| 07/03/2003 | CA2451993A1 Polypeptide, its conjugate with doxorubicin and conjugate-based pharmaceutical composition |
| 07/02/2003 | EP1323826A1 A cell line expressing mutated human tissue - type plasminogen activator, the constructing strategy thereof and method of preparing expressed protein |
| 07/02/2003 | EP1323824A2 Use of human keratinocyte growth factor-2 for the preparation of pharmaceutical compositions |
| 07/02/2003 | EP1323823A2 Mammalian secretory peptide 9, antibodes against it and their use |
| 07/02/2003 | EP1323737A2 Il-3 variant hematopoiesis fusion protein |
| 07/02/2003 | EP1323736A1 Chimeric human-type vascular endothelial cell growth factor |
| 07/02/2003 | EP1323735A1 Gene relating to drug tolerance and utilization thereof |
| 07/02/2003 | EP1323734A1 Irap-binding protein |
| 07/02/2003 | EP1323733A1 BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases |
| 07/02/2003 | EP1323732A1 Beta-catenin nuclear localizing protein |
| 07/02/2003 | EP1323730A1 Novel polypeptides and anti-hiv drugs containing the same |
| 07/02/2003 | EP1323436A1 Anti-adhesion barrier comprising carboxymethylcellulose and gellan gum |
| 07/02/2003 | EP1323433A1 Compositions for preventing urinary calculus |
| 07/02/2003 | EP1323427A1 Method for diagnosing and treating dentinogenesis imperfecta type ii by using dentin sialophosphoprotein (dspp) gene and its encoding product |
| 07/02/2003 | EP1323425A1 Composition for diminishing neutral fat in blood |
| 07/02/2003 | EP1323420A1 Remedies for inflammatory bowel diseases |
| 07/02/2003 | EP1322954A1 Method for treatment of insulin resistance in obesity and diabetes |
| 07/02/2003 | EP1322778A2 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas |
| 07/02/2003 | EP1322769A2 Protein phosphatases |
| 07/02/2003 | EP1322768A2 Isolation of drosophila and human polynucleotides encoding par-1 kinase, polypeptides encoded by the polynucleotides and methods utilizing the polynucleotides and polypeptides |
| 07/02/2003 | EP1322763A2 Listeria inocua , genome and applications |
| 07/02/2003 | EP1322762A2 Haemophilus influenzae antigens and corresponding dna fragments |
| 07/02/2003 | EP1322760A2 G-protein coupled receptors |
| 07/02/2003 | EP1322759A2 Potassium channel interactors and uses therefor |
| 07/02/2003 | EP1322758A2 Regulation of human g protein-coupled receptor |
| 07/02/2003 | EP1322757A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 07/02/2003 | EP1322755A1 Human and mouse targeting peptides identified by phage display |
| 07/02/2003 | EP1322752A2 Fad4, fad5, fad5-2, and fad6, fatty acid desaturase family members and uses thereof |
| 07/02/2003 | EP1322668A2 A novel human g-protein coupled receptor, hgprbmy7, expressed highly in spinal cord |
| 07/02/2003 | EP1322667A2 Tumor necrosis factor receptors 6-alpha and 6-beta |
| 07/02/2003 | EP1322659A1 21 human secreted proteins |
| 07/02/2003 | EP1322658A1 Oligonucleotide modulation of her-1 expression |
| 07/02/2003 | EP1322657A1 22 human secreted proteins |
| 07/02/2003 | EP1322616A2 Quinoline-(c=o)-(di-, tri- and tetrapeptide) derivatives as caspase inhibitors |